Roy Buchanan
Stock Analyst at JMP Securities
(2.07)
# 2,904
Out of 4,896 analysts
66
Total ratings
39.68%
Success rate
-4.49%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $59 | $50.54 | +16.75% | 6 | Jun 30, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.38 | +314.20% | 2 | Jun 17, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $23 → $24 | $6.56 | +265.85% | 13 | Jun 3, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.46 | +83.15% | 9 | May 28, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $10.58 | +193.01% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.06 | +88.68% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.36 | +1,223.53% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $55.64 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.19 | +236.13% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.75 | +1,760.96% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $8.25 | +300.24% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $1.19 | +488.24% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.17 | +57.73% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $560.24 | -20.03% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $11.22 | +42.60% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.81 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Jun 30, 2025
Maintains: Market Outperform
Price Target: $59
Current: $50.54
Upside: +16.75%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.38
Upside: +314.20%
Enanta Pharmaceuticals
Jun 3, 2025
Maintains: Market Outperform
Price Target: $23 → $24
Current: $6.56
Upside: +265.85%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.46
Upside: +83.15%
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $10.58
Upside: +193.01%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.06
Upside: +88.68%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.36
Upside: +1,223.53%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $55.64
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.19
Upside: +236.13%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.75
Upside: +1,760.96%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $8.25
Upside: +300.24%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.19
Upside: +488.24%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.17
Upside: +57.73%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $560.24
Upside: -20.03%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $11.22
Upside: +42.60%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.81
Upside: -